272 related articles for article (PubMed ID: 27373304)
1. ER/LA Opioid Analgesics REMS: Overview of Ongoing Assessments of Its Progress and Its Impact on Health Outcomes.
Cepeda MS; Coplan PM; Kopper NW; Maziere JY; Wedin GP; Wallace LE
Pain Med; 2017 Jan; 18(1):78-85. PubMed ID: 27373304
[TBL] [Abstract][Full Text] [Related]
2. ER/LA opioid REMS and accredited education: Survey results provide insight into clinical roles, educational needs, and learner preferences.
Kear C; McKeithen T; Robertson S
Subst Abus; 2017; 38(2):145-149. PubMed ID: 28418777
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the Extended-Release/Long-Acting Opioid Prescribing Risk Evaluation and Mitigation Strategy Program by the US Food and Drug Administration: A Review.
Heyward J; Olson L; Sharfstein JM; Stuart EA; Lurie P; Alexander GC
JAMA Intern Med; 2020 Feb; 180(2):301-309. PubMed ID: 31886822
[TBL] [Abstract][Full Text] [Related]
4. Risk Evaluation and Mitigation Strategies (REMS) for extended-release and long-acting opioid analgesics: considerations for palliative care practice.
Gudin J
J Pain Palliat Care Pharmacother; 2012 Jun; 26(2):136-43. PubMed ID: 22764852
[TBL] [Abstract][Full Text] [Related]
5. Class-wide REMS for extended-release and long-acting opioids: potential impact on pharmacies.
Matthews ML
J Am Pharm Assoc (2003); 2013; 53(1):e1-7. PubMed ID: 23636166
[TBL] [Abstract][Full Text] [Related]
6. Evolution of opioid risk management and review of the classwide REMS for extended-release/long-acting opioids.
Stanos S
Phys Sportsmed; 2012 Nov; 40(4):12-20. PubMed ID: 23306411
[TBL] [Abstract][Full Text] [Related]
7. Primary care physician opinion survey on FDA opioid risk evaluation and mitigation strategies.
Slevin KA; Ashburn MA
J Opioid Manag; 2011; 7(2):109-15. PubMed ID: 21561034
[TBL] [Abstract][Full Text] [Related]
8. Changes in misuse and abuse of prescription opioids following implementation of Extended-Release and Long-Acting Opioid Analgesic Risk Evaluation and Mitigation Strategy.
Bucher Bartelson B; Le Lait MC; Green JL; Cepeda MS; Coplan PM; Maziere JY; Wedin GP; Dart RC
Pharmacoepidemiol Drug Saf; 2017 Sep; 26(9):1061-1070. PubMed ID: 28758289
[TBL] [Abstract][Full Text] [Related]
9. Increase your Confidence in Opioid Prescribing: Marketing Messages in Continuing Medical Education Activities on ER/LA Opioids.
Goodwin B; Lim HD; Butler J; Paglia D; Dempsey MT; O Connor B; Fugh-Berman A
Pain Physician; 2021 Aug; 24(5):E529-E538. PubMed ID: 34323440
[TBL] [Abstract][Full Text] [Related]
10. SCOPE of Pain: An Evaluation of an Opioid Risk Evaluation and Mitigation Strategy Continuing Education Program.
Alford DP; Zisblatt L; Ng P; Hayes SM; Peloquin S; Hardesty I; White JL
Pain Med; 2016 Jan; 17(1):52-63. PubMed ID: 26304703
[TBL] [Abstract][Full Text] [Related]
11. Assessing the impact of the extended-release/long-acting opioid an-algesics risk evaluation and mitigation strategies on opioid prescrip-tion volume.
Divino V; Cepeda MS; Coplan P; Maziere JY; Yuan Y; Wade RL
J Opioid Manag; 2017; 13(3):157-168. PubMed ID: 28829517
[TBL] [Abstract][Full Text] [Related]
12. Changes in Mortality Involving Extended-Release and Long-Acting Opioids After Implementation of a Risk Evaluation and Mitigation Strategy.
Black JC; Bau GE; Rosen T; Cepeda MS; Wedin GP; Green JL; Dart RC
Pain Med; 2020 Jan; 21(1):92-100. PubMed ID: 30877807
[TBL] [Abstract][Full Text] [Related]
13. Controlled Substance Prescribing Patterns--Prescription Behavior Surveillance System, Eight States, 2013.
Paulozzi LJ; Strickler GK; Kreiner PW; Koris CM;
MMWR Surveill Summ; 2015 Oct; 64(9):1-14. PubMed ID: 26469747
[TBL] [Abstract][Full Text] [Related]
14. Issues and critiques of the forthcoming risk evaluation and mitigation strategy (REMS) for opioids in pain management.
Peppin JF; Coleman JJ; Kirsh KL
Issues Law Med; 2011; 27(2):91-119. PubMed ID: 22372206
[TBL] [Abstract][Full Text] [Related]
15. Extended-release/long-acting opioid REMS may fill the need for prescribers' appropriate use education.
Nicholson SC; Evanyo K; Salinas GD; Roepke N; Burton BS; Susalka D
J Opioid Manag; 2012; 8(4):212-6. PubMed ID: 22941848
[TBL] [Abstract][Full Text] [Related]
16. The changing landscape of opioid prescribing: long-acting and extended-release opioid class-wide Risk Evaluation and Mitigation Strategy.
Gudin JA
Ther Clin Risk Manag; 2012; 8():209-17. PubMed ID: 22570553
[TBL] [Abstract][Full Text] [Related]
17. Candidate metrics for evaluating the impact of prescriber education on the safe use of extended-release/long-acting (ER/LA) opioid analgesics.
Willy ME; Graham DJ; Racoosin JA; Gill R; Kropp GF; Young J; Yang J; Choi J; MaCurdy TE; Worrall C; Kelman JA
Pain Med; 2014 Sep; 15(9):1558-68. PubMed ID: 24828968
[TBL] [Abstract][Full Text] [Related]
18. Assessment of the FDA Risk Evaluation and Mitigation Strategy for Transmucosal Immediate-Release Fentanyl Products.
Rollman JE; Heyward J; Olson L; Lurie P; Sharfstein J; Alexander GC
JAMA; 2019 Feb; 321(7):676-685. PubMed ID: 30778596
[TBL] [Abstract][Full Text] [Related]
19. Opioid tolerance and urine drug testing among initiates of extended-release or long-acting opioids in Food and Drug Administration's Sentinel System.
Larochelle MR; Cocoros NM; Popovic J; Dee EC; Kornegay C; Ju J; Racoosin JA
J Opioid Manag; 2017; 13(5):315-327. PubMed ID: 29199397
[TBL] [Abstract][Full Text] [Related]
20. FDA Boxed Warning for Immediate-Release Opioids.
Food And Drug Administration Public Health Service U S Department Of Health And Human Services
J Pain Palliat Care Pharmacother; 2016 Jun; 30(2):141-5. PubMed ID: 27301692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
